Data / Drug companies / Hec Pharm USA Inc.
Hec Pharm USA Inc.: 29 products in the FDA NDC directory, labeler code 72303
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hec Pharm USA Inc. (labeler code 72303) lists 29 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 29 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 1, 2026.
The request: Watch Hec Pharm USA Inc. (FDA labeler code 72303): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72303
- Products in commercial distribution
- 29
- Packages
- 34
- Finished drugs by generic name
- 8
- Prescription products
- 29
- Over the counter products
- 0
- Flagged as original packager
- 29 of 29 products that carry the flag
- Started marketing in the last 12 months
- 16
- Earliest marketing start
- November 30, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 29 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 29 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Olanzapine | 10 | 49 |
| Rosuvastatin calcium | 4 | 34 |
| Tadalafil | 4 | 54 |
| Olmesartan medoxomil | 3 | 31 |
| Sildenafil | 3 | 53 |
| Febuxostat | 2 | 22 |
| Solifenacin succinate | 2 | 22 |
| Oseltamivir phosphate | 1 | 37 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 16 | 55.2% |
| Tablet | 8 | 27.6% |
| Tablet, orally disintegrating | 4 | 13.8% |
| Suspension | 1 | 3.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Solifenacin succinate | 72303-0832 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2026 |
| Solifenacin succinate | 72303-0831 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2026 |
| Rosuvastatin calcium | 72303-0830 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2026 |
| Rosuvastatin calcium | 72303-0829 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2026 |
| Rosuvastatin calcium | 72303-0828 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2026 |
| Rosuvastatin calcium | 72303-0827 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2026 |
| Febuxostat | 72303-0856 | Tablet | Generic drugs (ANDA) | April 10, 2026 |
| Febuxostat | 72303-0855 | Tablet | Generic drugs (ANDA) | April 10, 2026 |
| Olmesartan medoxomil | 72303-0850 | Tablet, film coated | Generic drugs (ANDA) | April 10, 2026 |
| Olmesartan medoxomil | 72303-0849 | Tablet, film coated | Generic drugs (ANDA) | April 10, 2026 |
| Olmesartan medoxomil | 72303-0848 | Tablet, film coated | Generic drugs (ANDA) | April 10, 2026 |
| Oseltamivir Phosphate | 72303-0851 | Suspension | Generic drugs (ANDA) | March 25, 2026 |
| Olanzapine | 72303-0844 | Tablet, orally disintegrating | Generic drugs (ANDA) | March 17, 2026 |
| Olanzapine | 72303-0843 | Tablet, orally disintegrating | Generic drugs (ANDA) | March 17, 2026 |
| Olanzapine | 72303-0842 | Tablet, orally disintegrating | Generic drugs (ANDA) | March 17, 2026 |
| Olanzapine | 72303-0841 | Tablet, orally disintegrating | Generic drugs (ANDA) | March 17, 2026 |
| Sildenafil | 72303-0847 | Tablet, film coated | Generic drugs (ANDA) | June 11, 2020 |
| Sildenafil | 72303-0846 | Tablet, film coated | Generic drugs (ANDA) | June 11, 2020 |
| Sildenafil | 72303-0845 | Tablet, film coated | Generic drugs (ANDA) | June 11, 2020 |
| Tadalafil | 72303-0825 | Tablet, film coated | Generic drugs (ANDA) | March 27, 2019 |
| Tadalafil | 72303-0824 | Tablet, film coated | Generic drugs (ANDA) | March 27, 2019 |
| Tadalafil | 72303-0823 | Tablet, film coated | Generic drugs (ANDA) | March 27, 2019 |
| Tadalafil | 72303-0822 | Tablet, film coated | Generic drugs (ANDA) | March 27, 2019 |
| Olanzapine | 72303-0840 | Tablet | Generic drugs (ANDA) | November 30, 2018 |
| Olanzapine | 72303-0839 | Tablet | Generic drugs (ANDA) | November 30, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.